AM Pharma
  • Home
  • About Us
    • About AM-Pharma
    • Leadership Team
    • Supervisory Board
    • Careers
  • Our approach
    • Our Product and MOA
    • Acute Kidney Injury (AKI)
    • Hypophosphatasia (HPP)
  • Partnering
  • Investors
  • Media Centre
    • Press Releases
    • Publications
  • Contact
  • Menu Menu

Home > Media Centre

Media Centre

Press releases

AM-PHARMA INITIATES PHASE 2 TRIAL OF ILOFOTASE ALFA FOR CARDIAC SURGERY-ASSOCIATED RENAL DAMAGE

16th January 2024
Trial will evaluate ilofotase alfa as a treatment to prevent…
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 Info /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png Info2024-01-16 10:00:032024-01-16 10:22:12AM-PHARMA INITIATES PHASE 2 TRIAL OF ILOFOTASE ALFA FOR CARDIAC SURGERY-ASSOCIATED RENAL DAMAGE

AM-PHARMA ANNOUNCES POSITIVE CLINICAL DATA FROM PHASE 1B STUDY EVALUATING ILOFOTASE ALFA IN HYPOPHOSPHATASIA PATIENTS

11th October 2023
• Ilofotase alfa demonstrates pharmacologically relevant effect…
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 Info /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png Info2023-10-11 10:10:522023-10-11 10:55:39AM-PHARMA ANNOUNCES POSITIVE CLINICAL DATA FROM PHASE 1B STUDY EVALUATING ILOFOTASE ALFA IN HYPOPHOSPHATASIA PATIENTS

AM-PHARMA ANNOUNCES UPDATED CLINICAL DEVELOPMENT STRATEGY

26th September 2023
Advancing ilofotase alfa into a Phase 2 study for lead indication…
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 Info /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png Info2023-09-26 10:00:162023-09-26 08:29:39AM-PHARMA ANNOUNCES UPDATED CLINICAL DEVELOPMENT STRATEGY

AM-PHARMA TO PRESENT DATA FROM PHASE 3 REVIVAL STUDY AT UPCOMING SCIENTIFIC CONFERENCES

9th March 2023
Principal investigator Professor Peter Pickkers to present…
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 Info /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png Info2023-03-09 00:00:472023-03-09 10:07:15AM-PHARMA TO PRESENT DATA FROM PHASE 3 REVIVAL STUDY AT UPCOMING SCIENTIFIC CONFERENCES

AM-PHARMA PROVIDES BUSINESS UPDATE AND OUTCOME OF PRE-PLANNED INTERIM FUTILITY ANALYSIS OF PHASE 3 REVIVAL STUDY

20th October 2022
Phase 3 REVIVAL study stopped per recommendation of data…
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 Info /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png Info2022-10-20 08:00:102022-10-20 10:09:48AM-PHARMA PROVIDES BUSINESS UPDATE AND OUTCOME OF PRE-PLANNED INTERIM FUTILITY ANALYSIS OF PHASE 3 REVIVAL STUDY

AM-PHARMA ANNOUNCES PUBLICATION OF IN VIVO ACUTE KIDNEY INJURY STUDY DEMONSTRATING ILOFOTASE ALFA’S DUAL PROTECTIVE MECHANISM

5th July 2022
Study shows ilofotase alfa protects against ischemia-reperfusion…
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 Info /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png Info2022-07-05 15:00:062022-07-05 15:58:04AM-PHARMA ANNOUNCES PUBLICATION OF IN VIVO ACUTE KIDNEY INJURY STUDY DEMONSTRATING ILOFOTASE ALFA’S DUAL PROTECTIVE MECHANISM
Page 1 of 512345

Publications

Phase‑3 trial of recombinant human alkaline phosphatase for patients with sepsis‑associated acute kidney injury (REVIVAL)

8th January 2024
View publication
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 Info /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png Info2024-01-08 11:29:102024-01-08 11:29:10Phase‑3 trial of recombinant human alkaline phosphatase for patients with sepsis‑associated acute kidney injury (REVIVAL)

AM-PHARMA TO PRESENT DATA FROM PHASE 3 REVIVAL STUDY AT UPCOMING SCIENTIFIC CONFERENCES

9th March 2023
Principal investigator Professor Peter Pickkers to present…
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 Info /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png Info2023-03-09 00:00:472023-03-09 10:07:15AM-PHARMA TO PRESENT DATA FROM PHASE 3 REVIVAL STUDY AT UPCOMING SCIENTIFIC CONFERENCES

Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury

24th October 2018
You can read the whole publication by clicking on this button View…
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 Info /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png Info2018-10-24 16:32:372021-04-22 13:56:24Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury

Effects of a human recombinant alkaline phosphatase during impaired mitochondrial function in human renal proximal tubule epithelial cells

22nd December 2016
View publication
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 Info /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png Info2016-12-22 16:50:262021-01-07 12:21:36Effects of a human recombinant alkaline phosphatase during impaired mitochondrial function in human renal proximal tubule epithelial cells

Effects of a human recombinant alkaline phosphatase on renal hemodynamics, oxygenation and inflammation in two models of acute kidney injury

17th October 2016
View publication
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 Info /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png Info2016-10-17 16:55:362021-01-07 12:21:42Effects of a human recombinant alkaline phosphatase on renal hemodynamics, oxygenation and inflammation in two models of acute kidney injury

Study protocol for a multicentre randomised controlled trial: Safety, Tolerability, efficacy and quality of life Of a human recombinant alkaline Phosphatase in patients with sepsis-associated Acute Kidney Injury (STOP-AKI)

27th September 2016
View publication
Read more
/wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png 0 0 Info /wp-content/uploads/2019/06/AM_Pharma_logo-300x35.png Info2016-09-27 16:53:262021-01-07 12:21:46Study protocol for a multicentre randomised controlled trial: Safety, Tolerability, efficacy and quality of life Of a human recombinant alkaline Phosphatase in patients with sepsis-associated Acute Kidney Injury (STOP-AKI)
Page 1 of 41234

  • Privacy Policy
© AM-Pharma B.V.
Website by BTTR
linkedin
Scroll to top

We use cookies to help us improve our website by collecting and reporting information on how you use it. For more information about how we use cookies please see our Cookies Policy

AcceptReject


How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only